Proto-Oncogene Proteins c-mdm2
"Proto-Oncogene Proteins c-mdm2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An E3 UBIQUITIN LIGASE that interacts with and inhibits TUMOR SUPPRESSOR PROTEIN P53. Its ability to ubiquitinate p53 is regulated by TUMOR SUPPRESSOR PROTEIN P14ARF.
| Descriptor ID |
D051736
|
| MeSH Number(s) |
D08.811.464.938.750.562 D12.776.624.664.700.185 D12.776.660.764
|
| Concept/Terms |
Proto-Oncogene Proteins c-mdm2- Proto-Oncogene Proteins c-mdm2
- Proto Oncogene Proteins c mdm2
- c-mdm2, Proto-Oncogene Proteins
- Mdm2 Protein
- Double Minute 2 Protein
- c-mdm2 Proto-Oncogene Protein
- Proto-Oncogene Protein, c-mdm2
- c mdm2 Proto Oncogene Protein
- Murine Double Minute 2 Protein
- Mdm-2 Protein
- Mdm 2 Protein
- MDMX Protein
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-mdm2".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-mdm2".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-mdm2" by people in this website by year, and whether "Proto-Oncogene Proteins c-mdm2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-mdm2" by people in Profiles.
-
CopA3 peptide inhibits MDM2-p53 complex stability in colorectal cancers and activates p53 mediated cell death machinery. Life Sci. 2023 Apr 01; 318:121476.
-
Molecular docking of anti-inflammatory drug diclofenac with metabolic targets: Potential applications in cancer therapeutics. J Theor Biol. 2019 03 21; 465:117-125.
-
The HBx protein of hepatitis B virus confers resistance against nucleolar stress and anti-cancer drug-induced p53 expression. FEBS Lett. 2013 May 02; 587(9):1287-92.
-
Pattern of expression of p53, its family members, and regulators during early ocular development and in the post-mitotic retina. Invest Ophthalmol Vis Sci. 2012 Jul 20; 53(8):4821-31.
-
Pleiotropic effects of p300-mediated acetylation on p68 and p72 RNA helicase. J Biol Chem. 2010 Oct 01; 285(40):30443-52.
-
Pifithrin-alpha decreases the radioprotective efficacy of a Podophyllum hexandrum Himalayan mayapple fraction REC-2006 in HepG2 cells. Biotechnol Appl Biochem. 2009 Jul 09; 54(1):53-64.
-
No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes. Urol Oncol. 2011 May-Jun; 29(3):319-23.
-
MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res. 2009 Feb 01; 15(3):933-42.
-
Concerted activation of the Mdm2 promoter by p72 RNA helicase and the coactivators p300 and P/CAF. J Cell Biochem. 2007 Aug 01; 101(5):1252-65.
-
Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer Lett. 2007 May 08; 249(2):209-19.